In conclusion, results in the first half of 2021 exceeded our expectations and reinforced the essential nature of our commercial brands to the people who rely on them. Despite typical uneven ordering patterns, demand for our products in the more than 75 countries where we do business is robust. BioMarin's commercial team continues to execute seamlessly and look forward to new product launches around the world over the coming quarters, should timing of approvals align with our expectations.